Introduction

Chronic wounds are a major public health issue resulting in a significant financial burden on the healthcare system [1,2]. Furthermore, these wounds can result in serious systemic infections, frequent hospitalizations, surgical procedures, and amputations of extremities which leads to severe emotional and physical stress for patients. The burden of chronic wounds is anticipated to rise even more significantly with an aging population, increasing chronic diseases such as diabetes and obesity, and a lack of investment in research funds to develop new treatment strategies. Collaborative efforts must be made towards understanding the various pathologies underlying this extensive health problem in order to develop novel therapeutic strategies.

In chronic wounds, a constant state of inflammation due to complex interactions between microbes and the wound microenvironment exists [3]. Wounds that fail to heal express high levels of various pro-inflammatory cytokines, decreased levels of anti-inflammatory cytokines, and exhibit markers of an enhanced host immune response. Biofilms, which are defined as communities of bacteria that have grown on

Abstract

Background: Chronic wounds are a serious medical condition affecting over 6 million people in the United States. Biofilms, which alter the host immune response and establish a microenvironment that prevents wound healing, are intimately associated with the development of chronic wounds. Current treatment options do not specifically target the underlying molecular mechanisms of biofilm pathology. Paracrine factors secreted by mesenchymal stem cells (MSCs) have been demonstrated to play an important role in wound healing. The objective of this study was to examine the effects of the paracrine factors secreted from MSCs on reducing infection and accelerating wound closure in biofilm-infected wounds.

Methods: MSCs were cultured by seeding on an extracellular matrix (ECM). The supernatant from MSCs containing paracrine factors were applied to mature Pseudomonas aeruginosa biofilms in vitro and the number of viable bacteria were quantitated. BALB/cJ mice were wounded and infected with P. aeruginosa biofilms and the paracrine factors from reprogrammed MSCs were applied topically. The wound surface area and colony forming units counts of the treatment group were compared to control (culture media) and biofilm (untreated) groups.

Results: The paracrine factors from MSCs grown on ECM were found to reduce P. aeruginosa biofilm growth significantly (P<0.01). Wounds in the treatment group had lower bacterial counts and an increased rate of wound closure compared to non-treated mice wounds.

Conclusion: The results indicate that paracrine factors from reprogrammed MSCs accelerated wound healing and reduced the bacterial burden in biofilm-infected wounds. Future studies are needed to further characterize this phenomenon.

Keywords: Stem cells; Paracrine factors; Wound healing
surfaces of tissues or medical devices protected by an extrapoly saccharide matrix, are becoming increasingly recognized as a major obstacle in proper healing [4]. Biofilms are often present in chronic non-healing wounds and inhibit the ability of the immune system to eradicate the bacteria, causing a constant pro-inflammatory response [5]. Therefore, a comprehensive approach to treat chronic wounds must be able to target biofilms. If a biofilm is suspected clinically, the only current definitive treatment is surgical debridement, which can be an invasive and ineffective treatment option. Therefore, novel treatment options are needed. One potential solution to this problem involves the use of stem cells, which could help to restore normal physiologic conditions and remove bacteria in the wound through the secretion of paracrine factors. Paracrine factors are defined as trophic factors released by stem cells in response to the microenvironment [6,7]. The multipotency of mesenchymal stem cells (MSCs) coupled with their immunomodulatory properties through specific paracrine interactions with the immune system in damaged tissues have made these cells an attractive option to accelerate the healing process in chronic wounds [8]. Accordingly, the objective of this study was to examine the effects of paracrine factors secreted from MSCs on reducing infection and accelerating wound closure in biofilm-infected wounds. We hypothesized that paracrine factors from MSCs could improve wound healing in biofilm-infected wounds.

**Methods**

**Mesenchymal stem cells**

Human MSCs were isolated from the iliac crest bone marrow of healthy donors after obtaining written informed consent. Institutional review board approval of the protocol was granted by Tulane University. MSCs were harvested from donors using previously described techniques [9]. Human MSCs were used between 2–6 passage numbers and were grown in alpha-minimum essential media (MEM) supplemented with 10% fetal bovine serum, 100 U/mL of penicillin, 100 µg/mL of streptomycin, and 100 U/mL of L-glutamine under standard tissue culture conditions. Prior to each experiment, MSCs were passaged, centrifuged, and resuspended to 10^7 cells/mL in alpha-MEM.

**Seeding of MSCs onto extracellular matrix**

MSCs were seeded onto porcine small intestinal submucosa (SIS; Surgisis Biodesign, Cook Surgical, West Lafayette, IN, USA) as previously described [10]. The SIS was cut into 5 mm discs and rehydrated in sterile phosphate-buffered saline for 15 minutes prior to use. Fifty microliters of cells (1.0×10^7) were added to each SIS disc of extracellular matrix (ECM) in the plate. Cells were incubated on the ECM for 30 minutes before the remainder of the well was filled with media. After 24 hours, ECM seeded meshes were moved to new wells to prevent the collection of paracrine factors from any MSCs growing on the bottom of the wells not on the mesh.

**Collection of MSC paracrine factors**

Cell culture media was completely exchanged 24 hours prior to collection of paracrine factors for the static/ECM seeded MSCs. The collected media was fractionated using 3 kDa Amicon Ultra-4 centrifugal filters (Millipore, Billerica, MA, USA) at 3,200 × g and stored at –20°C. Paracrine factors were collected at days 1, 3, and 7.

**Analysis of paracrine factors from MSC supernatant**

All samples were analyzed using the Milliplex Multi Analyte Profiling Human Cytokine/Chemokine 14 analyte premixed kit (Millipore) following the manufacturer’s instructions. Samples were assayed in duplicate wells (25 μL per well) and the mean was determined. The plates were read with a Bioplex analyzer (Bio-Rad, Hercules, CA, USA). Cytokine concentrations were calculated in pg/mL based upon an eight-point five-parameter logistic standard curve for each cytokine. The values were normalized at each time to the number of viable cells. The cytokines studied included: granulocyte macrophage colony stimulating factor (GM-CSF), interferon (IFN)-gamma, interleukin (IL)-1b, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, monocyte chemoattractant protein (MCP)-1, and tumor necrosis factor (TNF)-alpha.

**Bacterial growth**

*Pseudomonas aeruginosa* (strain PAO1) bacteria were grown in Luria-Bertani (LB) medium overnight. Cultures were diluted to 10^5 colony forming units (CFU) and 2 µL of each diluent was inoculated onto the surface of sterile filter paper (5 mm diameter, 0.2 µm pore size; Sigma Aldrich, St. Louis, MO, USA) embedded in an agar plate [11]. Biofilms were grown for 72 hours at 37°C and moved to a fresh agar plate at 24 and 48 hours. The 10^5 CFU were quantitated per membrane.

**Animals**

Adult BALB/cJ male mice (8–12 weeks old) obtained from the
Jackson Laboratory (Bar Harbor, ME, USA) were used for all experiments (n=17). All animals were housed in individual cages under constant temperature and humidity with a 12-hour light/dark cycle with access to chow and water ad libitum throughout the study. All animal procedures and care were reviewed and approved by the Tulane University Institutional Animal Care and Use Committee (IACUC No. #4261) and performed in accordance with all Association for Assessment and Accreditation of Laboratory Animal Care International and IACUC standards.

**Excisional wound protocol**

Mice were individually anesthetized with isoflurane. Hair was removed from the dorsal surface with a depilatory agent and rinsed with an alcohol wipe. The site was prepped with betadine and draped. Sterile technique was maintained throughout the entire procedure. A 5-mm punch biopsy was used to outline a pattern for the wound on one side of the mouse's dorsum. One wound was created per mouse. Full thickness wounds were created using Iris scissors to extend through the panniculus carnosus. A 10-mm square-shaped splint fashioned from a 0.5-mm thick silicone sheet (Grace Bio-Laboratories, Bend, OR, USA) was positioned with the wound centered within the splint. An immediate-bonding adhesive (Krazy Glue; Elmer’s Inc., Columbus, OH, USA) fixed the splint to the skin, followed by interrupted 4-0 PDS sutures to stabilize its position. A 10-mm square antimicrobial dressing (Telfa; Covidien, Mansfield, MA, USA) with a 5mm hole in the center to prevent contamination of the wound with any surrounding skin bacteria was placed over the silicone splint and the wound was dressed with a sterile semi-occlusive transparent film dressing (Tegaderm; 3M Health Care, St. Paul, MN, USA). This dressing did not contain any antimicrobial agents. The mice were wrapped around their midline with a self-adherent wrap (Coban; 3M Health Care) to protect the wound. All mice received the same type of dressing.

**Biofilm inoculation**

On post-surgery day 2, mice in the biofilm group (n=6) and the treatment group (n=6) were inoculated with $10^5$ CFU *P. aeruginosa* biofilms by inverting the filter paper and sliding the biofilm onto each individual wound. For the control arm, the wounds received sterile saline (n=5). Wounds were redressed with antimicrobial pads and a sterile occlusive Tegaderm dressing every 2 days. Thewounding strategy for this study is outlined in Fig. 1.

**Wound morphology**

Digital photographs of each wound were taken every 2 days. A camera was affixed onto a stand to allow for a standard distance to the mice. The area of each wound was measured in pixels using image analysis software (Image J, v1.44; NIH, Bethesda, MD, USA). Post-wounding measurements were normalized to the corresponding day 0 wound area and recorded as a percentage of the original wound area. Validation of area measurements was performed as previously described [12]. Briefly, a stencil was used to draw a perfect circle with an area equal to 1.99 mm$^2$ and the number of pixels was determined. Ten identical measurements were performed on wounds to obtain an average to use for other wounds. For each mouse, the wound size was compared to itself to express percentage change from the original wound size throughout the study period.

**Treatment**

Concentrated media (100 µL) from MSCs grown on SIS for 7 days was mixed with an equal amount of petroleum ointment (Aquaphor; Beiersdorf Inc., Wilton, CT, USA) and applied topically to each wound in the treatment group at post-surgery day 4. The same ointment without MSCs was applied to wounds of the other (control and biofilm) groups on the same day.

**Bacteriology of the wounds**

At post-surgery days 5, 7, and 9, mice were sacrificed from all three groups. A 5-mm punch biopsy was used to excise the wound. All tissues were weighed and homogenized in sterile saline. The homogenate was serially diluted and plated on LB agar and incubated at 37°C overnight to quantify CFU. Cardiac puncture was also performed at the time of sacrifice to obtain blood cultures and 0.1 mL was plated on LB agar and incubated at 37°C overnight.
**Histological analysis**

Wounds were harvested using a 10-mm punch biopsy and bisected at their largest diameter for staining. They were preserved in 10% formalin, embedded in paraffin, and stained with hematoxylin and eosin (H&E). A pathologist blinded to the samples evaluated the epithelial gap size in each sample with light microscopy at a magnification of 200×.

**Statistical analysis**

Data are presented as the mean ± standard error of the mean. The Shapiro-Wilk test was used to assess for normal distribution of the data (SPSS version 27; IBM Corp., Armonk, NY, USA). Significance of the treatment group compared to the biofilm group was determined using an unpaired two-tailed Student t-test. A P-value ≤0.05 was considered to be statistically significant. Supplementary Table 1 outlines the weight of the mice and the experimental strategy.

**Results**

**MSC supernatant and cytokine analysis**

Detectable levels of all 14 cytokines were found in the supernatant from MSCs grown on the ECM. Higher levels of the pro-inflammatory cytokines GM-CSF, IL-6, IL-8, and MCP-1 were detected after 7 days of growth. There was no change in levels of IFN-gamma, IL-1b, IL-2, IL-4, IL-7, IL-10, IL-12, IL-13, and TNF-alpha detected at 7 days.

**Mice physical health**

In pilot studies, it was determined that inoculums of biofilm >10^5 CFU led to a significant weight loss and mortality (data not shown). Therefore, the inoculum of 10^5 CFU was chosen. No mice were found to have >10^2 CFU in the blood cultures at the time of sacrifice. At day 0, the BALB/cJ mice ranged in weight from 20.7–31.6 g. Average weight in the control group was 26.1±1.7, average weight of the biofilm group was 28.2±0.5, and average weight of the treatment group was 26.2±0.6. No statistical significance was found (P>0.05).

**Histology**

To confirm the presence of delayed healing in infected wounds, H&E staining was performed to evaluate the samples for wound closure (Fig. 2). In the control group, a loss of the epidermal layer and the presence of a 2 mm ulcer was found at post-surgery day 5. The samples at post-surgery days 7 and 9 did not have ulcers. H&E analysis of the biofilm-infected wounds revealed a loss of epidermal layer and ulcer formation in all samples with the ulcer size ranging from 4–5 mm.
Fig. 2. Histology of wounds from control and biofilm mice (H&E stain, ×200).

Fig. 3. Photographs of gross wounds from mice groups (control, biofilm, and treatment).
Wound closure

Morphological changes in the wounds for all three groups during the course of the experiment are shown in Fig. 3. The control group wounds were consistent in morphology and did not display significant bleeding. The wounds almost completely closed by post-surgery day 9. Ulcers with thick purulent exudate formed on the biofilm group and were still apparent by post-surgery day 9 (post-infection day 7). The treatment group also demonstrated ulcer formation with resolution on post-surgery days 7 and 9 (post-infection days 5 and 7).

The control group had an average of 26.1%±6.5% of the original wound area by post-surgery day 9. In contrast, the biofilm group had an average of 81.4%±0.3% of the original wound remaining on post-surgery day 9 (post-infection day 7). The treatment group had 39.8%±10.2% of the original wound area remaining at post-surgery day 9 (post-infection day 7 and post-treatment day 5).

The biofilm control, which represented wounds infected with biofilm and treated only with ointment not containing any paracrine factors had 91.4% of the original wound area remaining at post-surgery day 9. All data were determined to be normally distributed (Supplementary Table 2). A statistically significant difference in the percentage of original wound remaining was found for the biofilm group versus the control group at post-surgery days 7 and 9 (P=0.03 and P<0.001). The wound areas remaining are shown in Fig. 4 and Table 1.

Bacteriology

The numbers of viable bacteria in wounds were quantified by plating tissue homogenates (Table 2). Control wounds had less than $10^2$ CFU/g tissue at each time point of sacrifice. The biofilm group had a consistent number of bacteria at post-surgery days 5, 7, and 9 with $1.9 \times 10^6$ CFU/g tissue, $8.0 \times 10^6$ CFU/g tissue, and $8.9 \times 10^6$ CFU/g tissue, respectively. The biofilm vehicle mouse had $6.4 \times 10^6$ CFU/g tissue of bacteria, which is consistent with the biofilm group. The treatment group had a similar number of bacteria at post-surgery day 5 ($6.2 \times 10^6$ CFU/g tissue) but had decreased numbers at post-surgery day 7 ($8.4 \times 10^5$ CFU/g tissue) and day 9 ($6.8 \times 10^5$ CFU/g tissue). PAO1 bacteria were differentiated from skin flora by colony size and morphology.

Discussion

Chronic wounds are a significant source of morbidity and mor-

![Fig. 4. Percentage of wound remaining in mice groups (control, biofilm, and treatment).](https://doi.org/10.22467/jwmr.2022.02040)
tality in the healthcare field. This study used a well-established \textit{in vivo} biofilm model \cite{13,14} to evaluate the treatment of biofilm-infected wounds with paracrine factors from MSCs. The results from this study suggest that the conditioned media from MSCs grown on an ECM for 7 days containing pro-inflammatory paracrine factors accelerated the rate of wound closure and decreased the bacterial burden in an animal model.

Previous studies have demonstrated that stem cells have an effect on the wound healing process \cite{8,15,16}. The paracrine factors from MSCs have also been studied for their role in wound healing \cite{17}. Chen et al. \cite{18} identified vascular endothelial growth factor-alpha, IGF-1, EGF, keratinocyte growth factor, angiopoietin-1, stromal derived factor-1, macrophage inflammatory protein-1 alpha and beta and erythropoietin secretion from MSCs compared to dermal fibroblasts. MSCs have been shown to secrete antimicrobial peptides, such as LL-37 and lipocalin-2 which may be important factors in the eradication of biofilms \cite{19}. These peptides have already been used to treat biofilms \textit{in vitro} with varying success \cite{20}. A recent study by Yang and colleagues demonstrated that co-culture of \textit{P. aeruginosa} biofilms with MSCs derived from human umbilical cords prevented the development of biofilms on an endotracheal tube presumably due to production of LL-37 \cite{21}. Further studies are needed to determine what specific paracrine factors of the conditioned media have measurable anti-biofilm properties that can influence wound healing \textit{in vivo}, and to identify additional paracrine factors which may be critical to the interactions of biofilm formation and wound healing.

There are few well-studied biofilm models and even fewer have been used to evaluate the different treatment strategies of biofilms \cite{22}. A study by Seth et al. \cite{22} investigated surgical debridement, lavage, and silver sulfadiazine in the treatment of biofilms using a rabbit ear model. They determined that the combination of all three treatment strategies improved wound healing significantly. A previous study by Hayward et al. \cite{23} found that when fibroblast growth factor was applied to chronic granulating wounds in rats, a significant acceleration in wound healing was observed but no change in the bacterial counts was found.

There are several limitations to this study. First, the number of mice for the treatment group was too low to reach statistical significance. In addition, mouse skin heals primarily by contraction in comparison to human skin which heals largely by epithelization. The healing process of the animal model was altered through using a silicon ring to prevent contraction, however, there are still some limitations with translating these results to human skin \cite{24}. Second, the time course could be increased to further evaluate the remodeling phase of wound healing. Mice were evaluated for 9 days in this experiment during the inflammatory and proliferative phases of wound healing. A longer time period wound be necessary to assess the chronic healing process \cite{13,14}. Finally, it is important to evaluate the effect of unprogrammed (i.e., static seeded) MSCs on the wounds to determine how cells grown in standard tissue culture conditions affect the bacterial counts. Previous studies have already demonstrated that these MSCs accelerate the rate of closure in aseptic wounds \cite{18,25}.

In conclusion, the results from this study demonstrated a novel treatment strategy for chronic wounds using the paracrine factors secreted from reprogrammed MSCs to decrease bacteria counts and accelerate wound closure in an animal study. Wound healing is a dynamic process that involves many different types of cells. Existing strategies to heal chronic wounds that focus on one or two agents are too simplistic. MSC-based paracrine factor therapies offer the advantage of several cytokines, growth factors, and peptides being secreted at different stages, which may be critical for the development of novel strategies to heal wounds.

**Conflict of interest**

No potential conflict of interest relevant to this article was reported.

**Acknowledgments**

We would like to thank Dr. Lisa Morici from Tulane University in New Orleans, LA for providing the bacterial strain. We would also like to acknowledge Dr. Donald Phinney from Scripps Institute in Juniper, FL for providing the mesenchymal stem cells. We also thank Dr. Rodney Shackelford from Tulane University in New Orleans, LA for providing the histologic analysis.

**ORCID iDs**

Alison A. Smith https://orcid.org/0000-0002-1742-3160
Charles F. Bellows https://orcid.org/0000-0002-2243-0517

**Supplementary material**

Supplementary Table 1. Data on mice weights and experimen-
Supplementary data can be found at: https://doi.org/10.22467/jwmr.2022.02040.

Supplementary Table 2. Results of Shapiro-Wilk normality test
Supplementary data can be found at: https://doi.org/10.22467/jwmr.2022.02040.

References

1. Nussbaum SR, Carter MJ, Fife CE, et al. An economic evaluation of the impact, cost, and medicare policy implications of chronic nonhealing wounds. Value Health 2018; 21:27-32.
2. Olsson M, Jarbrink K, Divakar U, et al. The humanistic and economic burden of chronic wounds: a systematic review. Wound Repair Regen 2019;27:114-25.
3. Goldberg SR, Diegelmann RF. What makes wounds chronic. Surg Clin North Am 2020;100:681-93.
4. Del Pozo JL. Biofilm-related disease. Expert Rev Anti Infect Ther 2018;16:51-65.
5. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284:1318-22.
6. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther 2012; 20:14-20.
7. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006;98:1076-84.
8. Duscher D, Barrera J, Wong VW, et al. Stem cells in wound healing: the future of regenerative medicine? A mini-review. Gerontology 2016;62:216-25.
9. Sekiya I, Larson BL, Smith JR, et al. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 2002;20:530-41.
10. Ahn HH, Kim KS, Lee JH, et al. Porcine small intestinal submucosa sheets as a scaffold for human bone marrow stem cells. Int J Biol Macromol 2007;41:590-6.
11. Anderl JN, Franklin MJ, Stewart PS. Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother 2000;44:1818-24.
12. Amos PJ, Kapur SK, Stapor PC, et al. Human adipose-derived stromal cells accelerate diabetic wound healing: impact of cell formulation and delivery. Tissue Eng Part A 2010;16:1595-606.
13. Zhao G, Usui ML, Underwood RA, et al. Time course study of delayed wound healing in a biofilm-challenged diabetic mouse model. Wound Repair Regen 2012;20:342-52.
14. Zhao G, Hochwalt PC, Usui ML, et al. Delayed wound healing in diabetic (db/db) mice with Pseudomonas aeruginosa biofilm challenge: a model for the study of chronic wounds. Wound Repair Regen 2010;18:467-77.
15. Kim SH, Nam JH, Lee MR, et al. Effects on wound healing of human-induced pluripotent stem cell-derived cells similar to endothelial colony-forming cells. J Wound Manag Res 2020;16:3-12.
16. Kirby GT, Mills SJ, Cowin AJ, et al. Stem cells for cutaneous wound healing. Biomed Res Int 2015;2015:285869.
17. Barbul A, Knud-Hansen J, Wasserkrug HL, et al. Interleukin 2 enhances wound healing in rats. J Surg Res 1986;40:315-9.
18. Chen L, Tredget EE, Wu PY, et al. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 2008; 3:e1886.
19. Krasnodembskaya A, Song Y, Fang X, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010;28:2229-38.
20. Batoni G, Maisetta G, Brancatisano FL, et al. Use of antimicrobial peptides against microbial biofilms: advantages and limits. Curr Med Chem 2011;18:256-79.
21. Yang H, Xu F, Zheng X, et al. Human umbilical cord mesenchymal stem cells prevent bacterial biofilm formation. Biomed Res Int 2022;2022:1530525.
22. Seth AK, Geringer MR, Gurjala AN, et al. Treatment of Pseudomonas aeruginosa biofilm-infected wounds with clinical wound care strategies: a quantitative study using an in vivo rabbit ear model. Plast Reconstr Surg 2012;129:262e-274e.
23. Hayward P, Hokanson J, Heggers J, et al. Fibroblast growth factor reserves the bacterial retardation of wound contraction. Am J Surg 1992;163:288-93.
24. Zomer HD, Trentin AG. Skin wound healing in humans and mice: challenges in translational research. J Dermatol Sci 2018;90:3-12.
25. Mishra PJ, Mishra PJ, Banerjee D. Cell-free derivatives from mesenchymal stem cells are effective in wound therapy. World J Stem Cells 2012;4:35-43.